CN118304400A - 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 - Google Patents

包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 Download PDF

Info

Publication number
CN118304400A
CN118304400A CN202410235521.9A CN202410235521A CN118304400A CN 118304400 A CN118304400 A CN 118304400A CN 202410235521 A CN202410235521 A CN 202410235521A CN 118304400 A CN118304400 A CN 118304400A
Authority
CN
China
Prior art keywords
vtp
tumor
treatment
bchl
pdt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410235521.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·舍茨
Y·所罗门
L·阿格美
R·哈姆瑞
D·普瑞斯
K·金姆
J·科尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Original Assignee
Yeda Research and Development Co Ltd
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Memorial Sloan Kettering Cancer Center filed Critical Yeda Research and Development Co Ltd
Publication of CN118304400A publication Critical patent/CN118304400A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410235521.9A 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法 Pending CN118304400A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
US62/320,549 2016-04-10
CN201780035366.4A CN109862918A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780035366.4A Division CN109862918A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Publications (1)

Publication Number Publication Date
CN118304400A true CN118304400A (zh) 2024-07-09

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410235521.9A Pending CN118304400A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法
CN201780035366.4A Pending CN109862918A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780035366.4A Pending CN109862918A (zh) 2016-04-10 2017-04-10 包括细菌叶绿素衍生物的用于治疗癌症的联合疗法

Country Status (14)

Country Link
US (2) US11278555B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442582A1 (cg-RX-API-DMAC7.html)
JP (2) JP2019510807A (cg-RX-API-DMAC7.html)
KR (2) KR20190008206A (cg-RX-API-DMAC7.html)
CN (2) CN118304400A (cg-RX-API-DMAC7.html)
AU (2) AU2017250732B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070847A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020067A1 (cg-RX-API-DMAC7.html)
IL (1) IL262191B2 (cg-RX-API-DMAC7.html)
MX (2) MX390751B (cg-RX-API-DMAC7.html)
RU (2) RU2021110230A (cg-RX-API-DMAC7.html)
SG (1) SG11201808849TA (cg-RX-API-DMAC7.html)
WO (1) WO2017179053A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807187B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
CN106458190B (zh) 2014-05-30 2019-12-06 戴科知识产权控股有限责任公司 具有喷射器、气动控制阀和可选择的吸气器的真空创建系统
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (ko) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201172B1 (pl) 1998-12-09 2009-03-31 Yeda Res & Dev Pd-Bakteriofeoforbid, sposób jego wytwarzania, kompozycja farmaceutyczna zawierająca go i jego zastosowanie
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
AU2009305893B2 (en) 2008-10-23 2014-03-27 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
MX2022003190A (es) 2022-04-11
EP3442582A1 (en) 2019-02-20
BR112018070847A2 (pt) 2019-02-05
RU2747258C2 (ru) 2021-04-29
US20190125769A1 (en) 2019-05-02
MX390751B (es) 2025-03-21
AU2017250732A1 (en) 2018-11-15
JP2022031823A (ja) 2022-02-22
SG11201808849TA (en) 2018-11-29
AU2017250732B2 (en) 2022-11-10
IL262191B2 (en) 2025-01-01
KR20190008206A (ko) 2019-01-23
IL262191A (en) 2018-11-29
IL262191B1 (en) 2024-09-01
CA3020067A1 (en) 2017-10-19
AU2023200591A1 (en) 2023-03-09
US20220202838A1 (en) 2022-06-30
JP2019510807A (ja) 2019-04-18
CN109862918A (zh) 2019-06-07
WO2017179053A1 (en) 2017-10-19
ZA201807187B (en) 2020-01-29
RU2018139523A (ru) 2020-05-15
RU2021110230A (ru) 2021-05-26
US11278555B2 (en) 2022-03-22
RU2018139523A3 (cg-RX-API-DMAC7.html) 2020-07-07
MX2018012392A (es) 2019-08-21
KR20220139445A (ko) 2022-10-14

Similar Documents

Publication Publication Date Title
Luo et al. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy
US20220202838A1 (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
Zhu et al. Tumor‐targeted nano‐adjuvants to synergize photomediated immunotherapy enhanced antitumor immunity
Guan et al. A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2, 3-dioxygenase
US20150344577A1 (en) Agents for treating tumors, use and method thereof
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
Liu et al. Immune-enhanced and tumor-targeted PDT cascade therapy for oral squamous cell carcinoma utilizing a carrier-free BRD4 inhibitor/PDT agent nanocomplex
KR102787188B1 (ko) 방광암에 대한 신보조 요법
KR101399591B1 (ko) 동시 화학요법 및 면역요법
JP2010528091A (ja) ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法
Tao et al. Synergistic strategy based on mild phototherapy and deep tumor hypoxia reversal comprehensively remodels the tumor microenvironment for improved immunotherapy
CA2358754A1 (en) Synergistic tumorcidal response induced by histamine
Zhou et al. A dual PROTAC nanocarrier amplifies DNA damage and STING activation for cancer immunotherapy
Zhang et al. Immunomodulating platelet-mimicking nanoparticles for AIE-based enhanced photodynamic immunotherapy against lung cancer
Wang et al. TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
Hu et al. Perivascular delivery of photothermal-immunotherapy nanovaccine bypasses blood circulation to enhance the antitumor immune response of breast cancer
EP3538221A1 (en) Non-adult human dosing of anti-cd30 antibody-drug conjugates
Lobo Immunological Effects of Photodynamic Therapy
Lou Applications of porphyrin nanoparticles in enhancing Cancer immunotherapies
Li et al. Transforming tumors into ‘high-risk bombs’ triggers a neoantigen storm and amplifies immune responses
Castro et al. Targeted photodynamic immunotherapy
Li et al. Fluence rate differences in photodynamic therapy efficacy and activation of immune checkpoints of murine colorectal cancer
Kane et al. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma
Zhang et al. Synergistic photodynamic therapy and IDO inhibition via a self-assembled nanomedicine potentiates PD-L1 blockade in gastrointestinal cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination